| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 4
| Issue : 1 | Page : 22-29 |
|
|
FGFR inhibitors: Emerging treatments in advanced or metastatic cholangiocarcinoma
Yasar Ahmed1, Raza Khan1, Mary O’Reilly1, Shane O’Sulivan1, Thamir Mahgoub2
1 Medical Oncology Department, St Vincent’s University Hospital, Dublin, Ireland
2 Medical Oncology Department, Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland
Correspondence Address:
Dr. Yasar Ahmed
Medical Oncology Department, St Vincent’s University Hospital, Merrion Rd, Dublin 4 D04 N2E0.
Ireland
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jco.jco_45_20
|
|
|
Cholangiocarcinoma (CCA) is an aggressive cancer with poor prognosis, where the median overall survival remains less than 1 year with standard treatment for unresectable or metastatic disease. This highlights the need for new therapeutic approaches. The fibroblast growth factor receptor (FGFR) family of transmembrane receptors, which are implicated in tumorigenesis, may represent one such target. In this article, we summarize the therapeutic rationale for targeting these receptors in CCA and the role of molecular testing to identify potential responders to treatment. We examine the current available safety and efficacy data on the several small molecule tyrosine kinase inhibitors under investigation for this disease. With a move toward identifying and targeting tumor specific mutations, FGFR inhibitors represent an exciting development which may be available for patients in the near future. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
